Hon CHRIS HIPKINS: There are a couple of reasons for that. One, of course, is that we made the decision not to rush the vaccine approval process, as many other OECD countries, who have been dealing with widespread outbreaks, chose to do, and New Zealanders ultimately can have good confidence in our vaccine programme because of that. It's been through a very thorough approvals process. And, yes, we have had the opportunity to draw on the clinical and field trials from other countries as a result of our decision to do that. The second is that we did make a decision to switch the way we were viewing our vaccine portfolio, to rely primarily on a Pfizer-based vaccine campaign. We had a variety of reasons for doing that. It did mean that some of the vaccine doses that we expected to arrive in the second quarter we have not taken delivery of, because we are increasing the deliveries of our Pfizer vaccine in the second half of the year.